Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells
Bisphosphonates such as alendronate are antiosteoporotic drugs that inhibit the activity of bone-resorbing osteoclasts and secondarily promote osteoblastic function. Diabetes increases bone-matrix-associated advanced glycation end products (AGEs) that impair bone marrow progenitor cell (BMPC) osteog...
Main Authors: | Sara Rocío Chuguransky, Ana María Cortizo, Antonio Desmond McCarthy |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2016/5891925 |
Similar Items
-
Antiosteogenic effect of arsenic trioxide, cholecalciferol, lovastatin or their combination in vitro
by: Gvozdenović-Jeremić Jelena, et al.
Published: (2019-01-01) -
Roles of fibrinolytic factors in the alterations in bone marrow hematopoietic stem/progenitor cells during bone repair
by: Kiyotaka Okada, et al.
Published: (2020-09-01) -
Bone Marrow Progenitors in Vascular Tissue Engineering
by: Fletcher, Joanne L.
Published: (2009) -
Characterisation of bone marrow progenitor cells in disease
by: Gowers, Kate Hayley Christine
Published: (2013) -
The susceptive alendronate-treatment timing and dosage for osteogenesis enhancement in human bone marrow-derived stem cells.
by: Chih-Hsiang Chang, et al.
Published: (2014-01-01)